Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a) by Frederick Berro Rivera, MD, Sung Whoy Cha, MD, Cruz Linnaeus Louisse, MD, Genquen Philip Carado, MD, John Vincent Magalong, MD, Vincent Anthony Tang, MD, Mary Grace Enriquez, MD, Martha Gulati, MD, MS, Byambaa Enkhmaa, MD, PhD, Neha Pagidipati, MD, MPH, Nishant P. Shah, MD

“…Objectives: The authors examined the effect of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) on plasma Lp(a) levels across multiple trials. …”
Get full text

Proprotein Convertase Subtilisin/Kexin Type 9: From the Discovery to the Development of New Therapies for Cardiovascular Diseases by Nicola Ferri

“…The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9), a secretory protein that posttranscriptionally regulates levels of low density lipoprotein receptor (LDLR) by inducing its degradation, has opened a new era of pharmacological modulation of cholesterol homeostasis. …”
Get full text

PCSK9 affects vascular senescence through the SIRT1 pathway by Yuqin Wang, Shaoqing Cao, Zhangyu Wang, Chengsi Li, Jiangping Ye, Yehong Liu, Tianhui Jin, Yuting Zhou, Wentao Su, Gangjun Zong

Subjects: “…Proprotein convertase subtilisin-type kexin 9…”
Get full text

Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− mice by Xiaocui Chen, Minghui Sun, Xiang Ma, Yitong Ma, Bangdang Chen

Subjects: “…proprotein convertase subtilisin/kexin type 9…”
Get full text

Optimal calorie restriction threshold: effect of FATmax exercise combined with different proportions of calorie restriction on hypercholesterolemia by Yuetong Wu, Li Zhang, Jing Li, Boyang Xue, Wenyuan Shang, Yingli Lu

Subjects: Get full text

Association of Insomnia, Lipid Profile, and Lipid-Lowering Medications: A Narrative Review by Fang Jia, Shun-Yi Shi, Si-Fan Fei, Min Zhou, Jian-Jun Li

Subjects: Get full text

Increased Expression of the Pro-Protein Convertase Furin Predicts Decreased Survival in Ovarian Cancer by Robert E. Page, Andrés J. P. Klein-Szanto, Samuel Litwin, Emmanuelle Nicolas, Raid Al-Jumaily, Peter Alexander, Andrew K. Godwin, Eric A. Ross, Russell J. Schilder, Daniel E. Bassi

“…Background: Proprotein convertases (PCs) are serine proteases that after restricted proteolysis activate many proteins that play a crucial role in cancer such as metalloproteinases, growth factors and growth factor receptors, adhesion molecules, and angiogenic factors. …”
Get full text

Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review by Ewelina Jakielska, Paweł Głuszak, Marta Walczak, Wiesław Bryl

“…Recent studies have highlighted the relationship between MAFLD and proprotein convertase subtilisin/kexin type 9 (PCSK9). Based on the available data, PCSK9 inhibitors appear to have beneficial effects in patients with MAFLD, and they may be a treatment option in the future. …”
Get full text

PCSK9 in T-cell function and the immune response by Yuying Wang, Xiaosheng Fang, Jiarui Liu, Xiao Lv, Kang Lu, Yingxue Lu, Yujie Jiang

“…Abstract Proprotein convertase subtilisin/kexin type 9 (PCSK9) was first reported in 2003 and confirmed to be strongly associated with familial hypercholesterolemia. …”
Get full text

Protective effect of alirocumab, a PCSK9 inhibitor, on the sciatic nerve of rats with diabetic peripheral neuropathy by Na Cui, Yonghao Feng, Ming Wang, Xiuyan Lu, Yongmei Huang, Yinghui Chen, Xiaohong Shi

“…Dyslipidemia has been considered a risk factor for diabetic peripheral neuropathy. Proprotein convertase subtilisin-like/Kexin 9 inhibitor (PCSK9) inhibitors are a new type of lipid-lowering drug currently in clinical use. …”
Get full text

Evolocumab-induced delayed skin hypersensitivity reaction in a patient with familial hypercholesterolaemia by Grzegorz Porebski, Alicja Dziadowiec

“…In this report, we describe a patient with a delayed cutaneous hypersensitivity reaction to evolocumab, a human monoclonal antibody directed against the serine protease proprotein convertase subtilisin/kexin type 9 used to reduce low-density lipoprotein concentrations in the treatment of familial hypercholesterolaemia. …”
Get full text

PCSK9: A Potential Therapeutic Target for Sepsis by Yuan Yuan, Wei Wu, Shanshan Sun, Yi Zhang, Zhi Chen

“…Sepsis is a life-threatening organ dysfunction syndrome caused by a dysregulated host response to infection. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is often upregulated in the presence of sepsis and infectious diseases. …”
Get full text

Association of the rs562556 PCSK9 Gene Polymorphism with Reduced Mortality in Severe Malaria among Malian Children by Olesya Fedoryak, Charles Arama, Issa Diarra, Bouréma Kouriba, Michel Chrétien, Majambu Mbikay

“…Recent evidence suggests that proprotein convertase subtilisin/kexin type 9 (PCSK9), a downmodulator of cellular uptake of blood cholesterol, also negatively impacts host immune response to microbial infection. …”
Get full text

PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation by Elena Dozio, Massimiliano Ruscica, Elena Vianello, Chiara Macchi, Clementina Sitzia, Gerd Schmitz, Lorenza Tacchini, Massimiliano M. Corsi Romanelli

“…Epicardial adipose tissue (EAT) has the unique property to release mediators that nourish the heart in healthy conditions, an effect that becomes detrimental when volume expands and proinflammatory cytokines start to be produced. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a proinflammatory mediator involved in atherosclerosis, is also produced by visceral fat. …”
Get full text

Isolation of PCSK9-specific nanobodies from synthetic libraries using a combined protein selection strategy by Apisitt Thaiprayoon, Yodpong Chantarasorn, Worrapoj Oonanant, Anongnard Kasorn, Phoomintara Longsompurana, Satita Tapaneeyakorn, Pinpunya Riangrungroj, Fabien Loison, Andrew C. Kruse, Matthew P. DeLisa, Dujduan Waraho-Zhmayev

“…This combined process enabled isolation of three unique Nb clones (NbT15, NbT21, and NbT22) that all bound specifically to a target antigen, namely proprotein convertase subtilisin/kexin type 9 (PCSK9) as well as a gain-of-function PCSK9 mutant (D374Y). …”
Get full text

The multifaceted anti-atherosclerotic properties of herbal flavonoids: A comprehensive review by Meiwen Huang, Xuena Xie, Rong Yuan, Qiqi Xin, Shudong Ma, Hongai Guo, Yu Miao, Chunyu Hu, Yizhun Zhu, Weihong Cong

“…Currently, the clinical management of AS relies predominantly on statins and proprotein convertase subtilisin/kexin type 9 inhibitors, which primarily aim to reduce low-density lipoprotein levels and have demonstrated some therapeutic efficacy. …”
Get full text

Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records. by Giulia Barbati, Caterina Gregorio, Arjuna Scagnetto, Carla Indennidate, Chiara Cappelletto, Andrea Di Lenarda

“…In the last years, Proprotein Convertase Subtilisin-Kexin type 9 inhibitors (PCSK9-i) has emerged as a key therapeutic target to lower LDL and were introduced for prevention of CV events. …”
Get full text

Conditional knockdown of hepatic PCSK9 ameliorates high-fat diet-induced liver inflammation in mice by Xue-Ying Zhang, Qing-Qing Lu, Yan-Jie Li, Shan-Rui Shi, Chao-Nan Ma, Miao Miao, Shou-Dong Guo

“…InstructionAccumulating evidence has shown that proprotein convertase subtilisin/kexin type 9 (PCSK9) is associated with inflammation in the vascular system. …”
Get full text

Familial Hypercholesterolemia: Genetics, Symptoms, Diagnosis and Treatment - A Literature Overview by Maciej Rutkiewicz, Sabina Przygodzka, Katarzyna Gadżała, Karolina Garbino, Katarzyna Brudniak, Antoni Szuścik, Magdalena Czyczerska

“…These are: LDL-Receptor (LDLR), Apolipoprotein B (ApoB), and Proprotein convertase subtilisin/kexin 9 (PCSK9). People who are affected by mutation have around thirteen times higher risk of coronary artery disease (CAD) and, in order to that, premature death. …”
Get full text

Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis by Jeff Clarke, Xiaofei Wang, Thomas Stinchcombe, Scott J Antonia, Jeffrey Crawford, Neal Ready, Konstantin H Dragnev, Lin Gu, Cameron Wood, James M Isaacs, Liliana Lyniv, Kent Weinhold, Jacob M Kaufman, Eziafa I Oduah, Betty C Tong, Dennis Wigle

“…Across all treated patients, four receiving neoadjuvant and four receiving adjuvant pembrolizumab experienced treatment-related adverse events of grade 3 or higher with no grade 5 events. Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) levels increased across our patient cohort over time from baseline until postsurgery and remained elevated at the end of treatment. …”
Get full text